Public involvement beyond clinical research studies by Flight, L. et al.
This is a repository copy of Public involvement beyond clinical research studies.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/153497/
Version: Published Version
Proceedings Paper:
Flight, L. orcid.org/0000-0002-9569-8290, Baxter, S. and Khan, S. (2019) Public 
involvement beyond clinical research studies. In: Trials. 5th International Clinical Trials 
Methodology Conference (ICTMC 2019), 06-09 Oct 2019, Brighton, UK. BioMed Central , 
p. 25. 
https://doi.org/10.1186/s13063-019-3688-6
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
MEETING ABSTRACTS Open Access
Meeting abstracts from the 5th
International Clinical Trials Methodology
Conference (ICTMC 2019)
Brighton, UK. 06-09 October 2019
Published: 22 October 2019
P-1
Abstract omitted
P-2
Some practical considerations in the design of multi-arm multi-
stage designs
Jerome Wulff, Nikolaos Demiris
Cambridge Clinical Trial Unit, Cambridge, United Kingdom
Trials 2019, 20(Suppl 1):P-2
Introduction: In the design of cancer clinical trials, one is often con-
cerned with a number of options in the event that several treatments
are of interest.
Methods: We explore in this work the distinct possibilities when four
treatments are available, one acting as control and three as poten-
tially efficacious alternatives. This design may be embedded within
the context of multi-arm multi-stage (MAMS) trials where one may
select a two- or three-stage design.
Potential Results: We explore the application of such designs, in-
cluding trade-offs between potential gains in the number of pa-
tients with additional stages contrasted with patients “lost” due
to practical considerations such as patients randomised in
dropped arms while waiting for interim analyses and inspection
by an Independent Data and Safety Committee. In addition, in
cancer studies one may focus on the primary end-point using a
time-to-event analysis or a binary outcome by looking at the
probability of (potentially progression-free) survival at a specific,
clinically meaningful, time point. The effect of such choices is ex-
tensively investigated.
Potential Relevance & Impact: We conclude with a discussion of the
available software for MAMS designs and their advantages and dis-
advantages in terms of accuracy.
P-3
The UK plasma based Molecular profiling of Advanced breast cancer
to inform Therapeutic CHoices (plasmaMATCH) Trial: A multiple
parallel-cohort, phase IIa platform trial aiming to provide proof of
principle efficacy for designated targeted therapies in patient
subgroups identified through ctDNA screening (CRUK/15/010)
Sarah Kernaghan1, Laura Moretti1, Lucy Kilburn1, Katie Wilkinson1, Claire
Snowdon1, James Morden1, Iain Macpherson2, Andrew Wardley3,
Rebecca Roylance4, Richard Baird5, Alistair Ring6, Nicholas Turner7,
Judith M Bliss1, on behalf of the plasmaMATCH Trial Management
Group
1Clinical Trials and Statistics Unit at The Institute of Cancer Research
(ICR-CTSU), United Kingdom; 2The Beatson West of Scotland Cancer
Centre, Glasgow, United Kingdom; 3The Christie NHS Foundation Trust,
Manchester, United Kingdom; 4University College London Hospitals NHS
Foundation Trust, London, United Kingdom; 5Cambridge University
Hospitals NHS Foundation Trust, Cambridge, United Kingdom; 6The
Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 7The
Institute of Cancer Research and The Royal Marsden NHS Foundation
Trust, London, United Kingdom
Trials 2019, 20(Suppl 1):P-3
Introduction: plasmaMATCH is a novel platform trial which assesses
the potential of circulating tumour DNA (ctDNA) screening to dir-
ect targeted therapies in advanced breast cancer (ABC) patients.
The trial recruited ahead of target and will report initial results
within 3years of first patient first visit demonstrating efficiency of
this design.
Methods: plasmaMATCH is an open-label, multi-centre phase IIa plat-
form trial, consisting of a ctDNA screening component and five paral-
lel treatment cohorts. Patients with an actionable mutation identified
at ctDNA screening are invited to enter Cohorts A-D to receive a tar-
geted treatment matched to the mutation identified (A: ESR1–ex-
tended-dose fulvestrant; B: HER2–neratinib+/-fulvestrant; C&D: AKT1
(or PTEN for Cohort D) –AZD5363+/-fulvestrant). Cohort E was added
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prevent adverse drug reactions looking more and more likely. It is es-
sential that the views of the public are included in this advancement.
We are designing an experiment to measure the general public’s
opinions about genetic testing to prevent adverse drug reactions.
This will take the form of a discrete choice experiment (DCE), a sur-
vey design which allows us to quantify preferences.
Methods: A DCE requires participants to ‘trade-off’ different aspects
of genetic testing. For example, we may find that people are willing
to wait an extra month to receive results if the accuracy of the test
was higher. Using this design allows us to provide quantitative an-
swers to the question of public preferences.
To ensure the generalisability, relevance, and accuracy of results,
qualitative work to inform DCE development is essential. We are
planning to use online questionnaires with a patient group and with
clinicians, followed up with focus groups with the general public. We
are hoping to use a market research company to administer the sur-
vey, as they have access to a UK-representative panel and can return
results within 48 hours.
Timing of Potential Results: At the time of abstract submission, we
are awaiting ethical approval to begin the study. Once this is re-
ceived, we anticipate spending 3 months on qualitative work, and 2
months for data analysis.
Potential relevance and impact: We are doing this to ensure that
the views of the general public are heard and can inform future
developments in personalised medicine. Quantifying using a DCE
provides clear results to policy-makers and clinicians. This in-
creases the likelihood of public acceptance of personalised medi-
cine interventions.
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Public involvement beyond clinical research studies
Laura Flight1, Susan Baxter1, Samaira Khan1,2
1School of Health and Related Research, University of Sheffield, United
Kingdom; 2NIHR Research Design Service, Yorkshire and the Humbe
Trials 2019, 20(Suppl 1):P-86
Background: Public involvement as advisors in health research stud-
ies is becoming an established norm. However, scrutiny of the litera-
ture indicates that public involvement is predominantly described in
clinical evaluation studies, such as trials of medical interventions. The
value and role of public involvement in studies which are theoretical
or methodological, such as the development of new statistical
methods, are less well reported. We aimed to explore the value of
having public advisors on these types of studies where, in contrast
to clinical studies, their input is not drawing on patient experience.
Methods: A qualitative study, using focus groups with members of
the public and with researchers, was used to explore the perceived
role and value of public advisors in types of health research which
are not clinical research studies. Focus groups were recorded, and
transcribed, and qualitative data analysis software was used to sys-
tematically store and retrieve data during thematic analysis.
Results: Fifteen public and nine researcher participants took part in
the study. Examination of the data suggested themes relating to po-
tential benefits from public involvement; challenges to involvement;
and opportunities provided. The data indicated potential for public
involvement at different stages of the research cycle in all studies, in-
cluding those which are more theoretical or methodological in na-
ture, such as methods development in clinical trials.
Discussion: Involving the public as advisors in all forms of research
adds value, and the study confirms that involvement should not be
confined to research evaluating clinical interventions. The study pro-
vides information for health researchers in areas where public in-
volvement may be less established, such as methods development in
clinical trials. Involvement in these research areas has the potential
to add diverse forms of knowledge, provide legitimacy, and aid
impact.
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Co-designing a virtual world with young service users to deliver
social cognition therapy
Doctor Alba Realpe1, Farah Elahi2, Doctor Sandra Bucci3,6, Max
Birchwood2, Ivo Vlaev4, David Taylor5, Doctor Andrew Thompson2,7
1Population Health Sciences, University Of Bristol, Bristol, United
Kingdom; 2Mental Health and Wellbeing Division, Warwick Medical
School, University of Warwick, Coventry, United Kingdom; 3Greater
Manchester Mental Health NHS, Foundation Trust, Manchester, United
Kingdom; 4Behavioural Science Group, Warwick Business School,
University of Warwick, Coventry, United Kingdom; 5Department of
Surgery & Cancer, Faculty of Medicine, Imperial College London,
London, United Kingdom; 6Division of Psychology and Mental Health,
University of Manchester, Manchester, United Kingdom; 7Centre for
Youth Mental Health, University of Melbourne, Melbourne, Australia
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Introduction: Involving service users in the design and conduct of re-
search has been encouraged in government policy, but it is rarely
achieved, especially at trial initial stages. Co-design implies genuine
partnership in the generation of knowledge between service users
and researchers. This paper shows a step-by-step co-design approach
used to adapt an existing manualised social cognition intervention
for people with a first episode of psychosis to a virtual world
environment.
Methods: Clinical researchers, IT programmers and a group of young
people who have used mental health services were invited to partici-
pate in the design of a virtual environment to deliver an accessible
social cognition intervention to a hard to engage service user group.
An iterative process between service users and the design team was
set up and included developing initial ideas, creating a prototype
and testing the virtual world.
Results: Twenty young service users of local mental healthcare ser-
vices participated in the design and planning of intervention deliv-
ery. Young people felt the virtual environment should be familiar,
urban spaces, akin to therapy rooms or classrooms they have used in
real-life situations rather than non-traditional therapy spaces that
were initially proposed. Findings reflected the demographic makeup
of the sample.
Discussion: After the co-design process, the specific design, ap-
proach and protocol was tested in a proof-of-concept trial with
young people who experienced a first episode of psychosis. Young
service users were integral to an agile and iterative design. Techno-
logical innovations should be routinely co-designed and coproduced
if they are to realise their potential to deliver acceptable and afford-
able mental health interventions.
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The benefit of a Lived Experience Advisory Panel (LEAP) in the
design and conduct of a clinical trial into depression
Yvette Walters1, Niamh Quann1, Eleanor Taylor1, John Gledhill2, Peter
Bates2, Rachel Hobson1, Richard Morriss2
1University Of Leicester Clinical Trials Unit, Leicester, United Kingdom;
2University of Nottingham, Nottingham, United Kingdom
Trials 2019, 20(Suppl 1):P-88
Introduction/Aims: This trial is investigating Transcranial Magnetic
Stimulation (TMS) as a treatment for patients with moderate to se-
vere treatment resistant depression. From the outset the research
team were keen to involve service users or carers with lived experi-
ence of managing depression, in order to optimise engagement with,
and retention of participants.
Methods: Throughout the trial set up and current phase of recruit-
ment we have imbedded LEAP in all activities by: -scheduling on-
going quarterly (LEAP) meetings; involving members who either
have received TMS treatment, participated in previous TMS trials, or
have experience of treatment resistance depression, all local to the
Trials 2019, 20(Suppl 1):579 Page 25 of 141
